International Journal of Urology · 2021 · 19 citations · 24 references
MedicineNuclear MedicineOncologyBone MetabolismBone ScintigraphyMetastasisBone MetastasisBone Metastasis ImagingBone Tumor ImagingMetabolic Bone DiseaseMetastatic Bone DiseaseProstate CancerBone Tumor PrognosisMetastatic Castration-resistant Prostate CancerMortality RatesPrognostic Factors AnalysisPrognostic IndicesRadionuclide Bone ScintigraphyWhole-body Bone ScanWhole-body Bone Scintigraphy
Objective To determine prognostic factors including the Bone Scan Index in prostate cancer patients receiving standard hormonal therapy and chemotherapy. Methods This multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index study involved 30 hospitals and enrolled 247 patients (age 71 ± 8 years) with metastatic hormone‐sensitive prostate cancer ( n = 148) under hormone therapy and metastatic castration‐resistant prostate cancer ( n = 99) under chemotherapy. The Bone Scan Index (%) was determined by whole‐body bone scintigraphy using 99m Tc‐methylenediphosphonate. Patients were classified into tertiles and binary groups, and predictors of all‐cause death including Bone Scan Index, prostate‐specific antigen, and bone metabolic markers were determined using survival and proportional hazard analyses. Results During a mean follow‐up period of 716 ± 404 days, 81 (33%) of the patients died, and 3‐year mortality rates were 20% and 52% in the metastatic hormone‐sensitive prostate cancer and metastatic castration‐resistant prostate cancer groups, respectively. Survival analysis showed that a Bone Scan Index >3.5% was a significant determinant of death in the metastatic hormone‐sensitive prostate cancer group, whereas prostate‐specific antigen >55 ng/mL before chemotherapy was a determinant of prognosis in the metastatic castration‐resistant prostate cancer group. A Bone Scan Index >3.5% was also associated with a high incidence of prostate‐specific antigen progression in the metastatic hormone‐sensitive prostate cancer group. Patients with metastatic hormone‐sensitive prostate cancer and a better Bone Scan Index response (>45%) to treatment had lower mortality rates than those without such response. Conclusion The Bone Scan Index and hot spot number are significant determinants of 3‐year mortality, and combining the Bone Scan Index with prostate‐specific antigen should contribute to the management of prostate cancer patients with bone metastasis.
24
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations
Pharmacy, Oncology, Pharmacotherapy +17